Verseon presents anticancer drug candidates targeting multidrug resistant cancers
Verseon’s drug candidates target cancer cells by inhibiting the protein tubulin, which leads to cell cycle arrest
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Research
Helperby Therapeutics announces phase 1 results demonstrating multiple benefits of its unique…
Helperby Therapeutics presented data at European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) announcing…
Lupin’s steady stride on biosims
Lupin’s biosimilar plans are reaching a crucial inflexion point, with recent positive global Phase III results of its etanercept…
Berry pigments can open new avenues for cancer treatment
The pigments can regulate a key enzyme in cancer cells
Lesaffre Human Care launches scientific papers on women’s health
Promising anti-fungal and anti-inflammatory properties for vaginal candidiasis therapy
Failure of the antimicrobials: A crisis at the door-step
MK Chattopadhyay, Retired Senior Principal Scientist, Centre for Cellular and Molecular Biology (CSIR), talks about the urgent…
YLB’s phase III clinical trial of Etanercept biosimilar meets positive outcome
The study was a multinational randomised double-blind controlled trial of 52 weeks duration which included more than 500 patients…
Cancer targeted with reusable ‘stinging nettle’ treatment
Cancer cells are killed more effectively and selectively with a new approach, using a substance found in stinging nettles and…
Chronic disease treatment calls for innovation
India has already become the world capital of diabetes and heart diseases, and is set to acquire the same dubious distinction in…
Making India a global R&D leader: Opportunities and challenges
By Biten Kathrani, Director R&D, Asia Pacific, Boston Scientific outlines the trends which will drive progress in the R&D…
KRABEVA will be an important addition to our oncology portfolio of novel biologics as well as…
Biocon has recently launched a biosimilar in the Indian market. Suresh Subramanian, Sr Vice President & Head Branded…
Roche drug cocktail doubles chance of holding lung cancer at bay
37 per cent of patients in a closely watched clinical trial who received Tecentriq, Avastin and chemotherapy reached the one-year…
Novartis combo therapy for melanoma gets FDA priority review
The review covers combination therapy for the adjuvant treatment of patients with stage III melanoma
Trial results of Zika vaccine Sanofi dropped show promise
The ZPIV vaccine, made from inactivated Zika virus particles, was developed by US Army researchers, who in July 2016 had agreed to…
FDA approves Novo Nordisk diabetes drug Ozempic
The company said it plans to price the drug at $676 per prescription, which it described as ‘at parity’ to current market-leading…
FDA approves heart protection claims for Amgen cholesterol drug
A study released in March of more than 27,500 patients showed that Repatha cut the risk of heart attacks by 27 per cent and stroke…
Cancer drug prompts ‘drastic’ HIV decrease in lung cancer patient
Opdivo, or nivolumab is a PD-1 inhibitor, designed to help the body’s own immune system fend off cancer by blocking a protein…
FDA aims to approve more drugs based on early clinical data
Cancer drugs that cause tumours to shrink are considered likely to confer a meaningful clinical benefit, such as survival
Men more likely to develop serious heart condition, infective endocarditis, as women: Study
The new study allows prevention measures to be targeted at those individuals most at risk of developing IE
FDA OKs Mylan’s biosimilar of Roche cancer drug Herceptin
Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision